Much has happened since we last posted an update: At least 4 new papers were published by members of the CCC: Dr. Dinkova-Kostova was a co-author of a very exciting paper in Nature that describes a Krebs cycle derivative that is a crucial anti-inflammatory metabolite which also regulates type I interferons. This discovery may yield… Read more »
Posts Categorized: Autism
Our new paper has just been posted in the journal Global Advances in Health and Medicine. It is entitled “Sulforaphane from Broccoli Reduces Symptoms of Autism: A Follow-up Case Series from a Randomized Double-blind Study“. In this paper we present the edited testimonials of caregivers of subjects who received sulforaphane as part of the original study… Read more »
Dr. Fahey recently talked about the edible tropical tree Moringa on SmartDrugSmarts, with host Jesse Lawler and Lisa Curtis. In this 38 minute podcast Fahey discussed research on Moringa at the Chemoprotection Center, including their plans to evaluate it in the clinic.
We have been pleasantly surprised to see a series of very understandable, and well documented videos appear recently. They are unsolicited, and we have no connection to the narrator or his organization, nor were we interviewed for them. They do a good job of presenting some concepts (and in a couple of them they very… Read more »
Jed Fahey, Sc.D. on Isothiocyanates, the Nrf2 Pathway, Moringa & Sulforaphane Supplementation Released Jan 06, 2017 Preview YouTube video Jed Fahey, Sc.D. on Isothiocyanates, the Nrf2 Pathway, Moringa & Sulforaphane Supplementation Watch the Webinar or Listen to the Podcast (available via FoundMyFitness.com on iTunes and Sticher)
In response to the many questions we’ve received as follow-up to Dr. Fahey’s interview with Rhonda Patrick (FoundMyFitness.com), we have added a page with FAQs to this website, that we hope will answer some of the more commonly asked questions. At the moment, the volume of questions coming in from this website, Twitter and Facebook is… Read more »
Answers to frequently asked questions about the Autism study involving Sulforaphane
Autism is a life-long, complex neurodevelopmental disorder, characterized by difficulties in communication and social interaction and by stereotypic, repetitive behavior.
In a randomized, placebo-controlled, double-blind clinical study, daily administration of sulforaphane to young male patients with moderate to severe autism (26 on sulforaphane, 14 on placebo) substantially (and reversibly) improved many aspects of behavior in the majority of those who received sulforaphane.